In that trial , progression-free survival was significantly improved in the pazopanib arm ( median , @ vs @ months ; hazard ratio , @ ; P < @ ) , and toxicity of pazopanib consisted mainly of fatigue , diarrhea , nausea , weight loss , and hypertension .